New drug combo aims to extend life in advanced stomach cancer
Disease control
Recruiting now
This study tests a new drug, utidelone, combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination shrinks tumors and helps patients live longer. About 778 adults…
Phase: PHASE2, PHASE3 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC